On December 4, 2012, the FDA asked drug manufacturers to recall all 32 mg dose Zofran (ondansetron hydrochloride) products. This dose has been found to cause cardiac risks such as QT interval prolongation, which can lead to a potentially fatal heart rhythm known as Torsades de Pointes.
Spangenberg Shibley & Liber LLP's defective and dangerous drug injury attorneys are investigating abnormal heart rhythm claims on behalf of those who were injured while taking the 32 mg dose of Zofran. Zofran is commonly given to chemotheraphy, radiation therapy, and surgery patients to prevent nausea, according to the FDA's website.
Click here for more information about the Zofran lawsuit.
Click here to contact our dangerous and defective drug injury attorneys.